Daniel D. Billadeau, Ph.D. obtained his graduate degree from the University of Minnesota, Mpls, MN in 1996. He did his postdoctoral training with Dr. Paul Leibson at Mayo Clinic in the area of molecular immunology/biochemistry before beginning his independent research career in the Division of Oncology Research at Mayo Clinic in January of 2001. Presently, Dr. Billadeau is Professor and Chair of the Department of Immunology, is Deputy Director for Basic Science in the Mayo Clinic Comprehensive Cancer Center and is the Edmond A. and Marion F. Guggenheim named professor. Dr. Billadeau’s research efforts have focused on identifying molecular targets in pancreatic adenocarcinoma (PDAC), and his group was the first to demonstrate that glycogen synthase kinase-3β is overexpressed and nuclear localized in PDAC and is a viable therapeutic target.

 Daniel D. Billadeau, Ph.D. obtained his graduate degree from the University of Minnesota, Mpls, MN in 1996. He did his postdoctoral training with Dr. Paul Leibson at Mayo Clinic in the area of molecular immunology/biochemistry before beginning his independent research career in the Division of Oncology Research at Mayo Clinic in January of 2001. Presently, Dr. Billadeau is Professor and Chair of the Department of Immunology, is Deputy Director for Basic Science in the Mayo Clinic Comprehensive Cancer Center and is the Edmond A. and Marion F. Guggenheim named professor. Dr. Billadeau’s research efforts have focused on identifying molecular targets in pancreatic adenocarcinoma (PDAC), and his group was the first to demonstrate that glycogen synthase kinase-3β is overexpressed and nuclear localized in PDAC and is a viable therapeutic target.